Medmira

What Medmira does

MedMira Inc. is a Canadian in-vitro diagnostics company founded in 1993 in Halifax, Nova Scotia, and publicly listed on the TSX Venture Exchange (MIR) and OTC (MMIRF). The company develops, manufactures, and commercializes rapid diagnostic tests built on its patented Rapid Vertical Flow (RVF) Technology — a flow-through membrane platform that captures biomarkers from whole blood, serum, or plasma and delivers a visual result in under three minutes using a three-step procedure with no specialized equipment, refrigeration, or precision pipetting. The platform supports single-analyte cartridges (Reveal for HIV-1/2, TP/Syphilis, HCV), multiplex panels (Multiplo for TP/HIV, HCV/HIV, HBc/HIV/HCV, TP/HIV/HCV), research-use-only products (Miriad, distributed through VWR/Medline/McKesson), respiratory antigen tests (VYRA), and emerging platforms including MEDDUO (dual-window antigen/antibody with up to 8 analytes) and MiROQ (a quantitative SERS-based liquid biopsy system with AI-assisted analysis). Regulatory approvals span FDA, Health Canada, CE mark, China CFDA, and UN agencies (USAID, WHO, UNDP, UNFPA), with ISO 13485:2016/MDSAP certified manufacturing.

The company sells through a multi-tier distribution network — VWR, Medline, McKesson for research products; Lovell Government Services for US VA/DoD; Trimedic (exclusive) for Canada; and MediGroup for US physician practices — supplemented by direct enterprise sales, OEM/private-label partnerships, technology licensing, contract manufacturing, and the Miriad RVF Toolkit for academic and biotech assay development. Customer segments span point-of-care clinicians, blood/tissue/eye banks (one tissue-bank customer reports a 40% discard-rate reduction), public-health agencies (e.g., Public Health Winnipeg), and government/military healthcare programs. Named research partners include Johns Hopkins University Applied Physics Laboratory (saliva-based STI validation), Washington State University (Trichomonas vaginalis), and REACH Nexus (Multiplo TP/HIV self-test clinical trial).

The business model blends hardware sales of regulated diagnostic kits with technology licensing, OEM/private-label contracts, consulting and TAG conjugation services, and contract manufacturing. Pricing is not publicly disclosed and is set via direct negotiation through [email protected] and regional distributors. MedMira holds granted patents across the US, EU, China, and Canada covering both its core RVF architecture and the MiROQ SERS detection method, and has secured regulatory milestones including 2024 US FDA approval for its advanced G4 HIV-1/2 test and 2025 Health Canada approval for the Reveal TP Syphilis test.

Name

Medmira

Legal name

MedMira Inc.

Website

https://medmira.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

MedMira is a publicly traded Canadian in-vitro diagnostics company that develops and manufactures rapid diagnostic tests built on its patented Rapid Vertical Flow (RVF) Technology, serving point-of-care clinicians, government and military healthcare programs, blood/tissue banks, and research institutions worldwide.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostic Devices (Rapid Diagnostic Tests)

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

Keywords

• Rapid diagnostic tests
• Point-of-care diagnostics
• Infectious disease screening
• Multiplex immunoassays
• In vitro diagnostics

Headquarters

HQ city

Halifax

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Rapid Diagnostic Test Products: MedMira generates revenue primarily through the sale of rapid diagnostic test products including Reveal (single-analyte), Multiplo (multiplex), and Miriad (research use only) product lines. Products are sold through distribution partners and direct sales in multiple formats (POC, LAB+, LAB S/P).
2. Technology Licensing and Contract Services: MedMira offers licensing agreements, consulting services, TAG conjugation services, and the Miriad RVF Toolkit for researchers to develop rapid diagnostic tests using RVF Technology. The company also provides contract manufacturing services and technical conversion services for platform conversions.
3. OEM and Partner Solutions: OEM (Original Equipment Manufacturer) and private label models allow partners to define their own product positioning and branding while relying on MedMira's established technology, in-house manufacturing, and clear path to commercialization.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

MedMira designs, manufactures, and sells rapid diagnostic test kits built on its patented Rapid Vertical Flow (RVF) Technology platform. The product portfolio includes single-analyte tests (Reveal series for HIV-1/2, Syphilis, HCV), multiplex tests (Multiplo series for simultaneous detection of multiple infections), research-use-only products (Miriad series), and emerging quantitative platforms (MiROQ with SERS). Products are sold globally through distribution partners and direct enterprise sales to healthcare providers, blood/tissue banks, government agencies, and research institutions.

Product overview

MedMira offers a comprehensive portfolio of rapid diagnostic solutions organized across multiple product lines built on the proprietary RVF Technology™ platform. The Reveal® series provides single-analyte rapid tests for HIV-1/2, Syphilis (TP), and Hepatitis C. The Multiplo® series delivers multiplex solutions combining multiple analytes (TP/HIV, HCV/HIV, HBc/HIV/HCV, TP/HIV/HCV) in single cartridges for comprehensive infection screening. The Miriad® line offers Research Use Only (RUO) versions of these tests available globally without regulatory barriers. The MEDDUO™ platform enables advanced dual-window antigen and antibody detection with interference-free results, while the emerging MiROQ™ system combines RVF with SERS technology for quantitative liquid biopsy diagnostics with AI-powered analysis. The RVF Toolkit enables researchers to develop custom rapid tests using the platform technology.

Differentiator

Problem solved

Functional benefit

Brands

• Reveal: Single determination rapid tests for targeted screening and diagnostic purposes including HIV-1/2, TP (Syphilis), and HCV.
• Multiplo
• Miriad
• RVF Toolkit
• MiROQ
• MEDDUO
• VYRA

Products and services

• Reveal G4 Rapid HIV-1/2 Antibody Test FDA-approved and Health Canada-approved rapid test for accurate detection of HIV-1 and HIV-2 antibodies in whole blood, plasma, or serum using RVF Technology. Provides instant results in a three-step process with 99.64% HIV-1 sensitivity and 100% HIV-2 sensitivity, designed for healthcare professionals performing point-of-care HIV screening.
• Reveal TP (Syphilis) Antibody Test Health Canada-approved rapid test for detection of antibodies to Treponema pallidum (syphilis bacteria) in whole blood. Designed for point-of-care use with 97.3% sensitivity (RPR titre≥1:8) and 99.2% specificity, targeting clinicians and public health programs addressing syphilis screening.
• Reveal HCV Antibody Test Rapid test for accurate detection of Hepatitis C antibodies in whole blood, plasma, or serum using RVF Technology with a three-step procedure delivering instant, reliable results for healthcare professionals.
• Multiplo Complete Syphilis (TP/nTP) Antibody Test Multiplex rapid test detecting both treponemal (TP) and non-treponemal (nTP) antibodies in one assay, combining screening and confirmation in a single device. Currently in clinical trials for Health Canada approval, designed for syphilis screening programs.
• Multiplo Rapid TP/HIV Test Health Canada-approved multiplex rapid test for simultaneous detection of antibodies to Treponema pallidum (syphilis) and HIV-1/2 from a single blood sample. Achieves 97.3% sensitivity for TP (≥1:8 titre) and 100% sensitivity for HIV-1/2, designed for comprehensive STI screening at point-of-care.
• Multiplo Rapid HCV/HIV Antibody Test Multiplex rapid test for simultaneous detection of HIV-1/2 and Hepatitis C virus antibodies in whole blood, serum, and plasma specimens. Available for international markets outside North America and EU, targeting comprehensive bloodborne pathogen screening.
• Multiplo Rapid HBc/HIV/HCV Antibody Test Three-analyte multiplex rapid test detecting HIV-1/2, Hepatitis B core antigen (HBc), and Hepatitis C virus antibodies simultaneously. Demonstrates 96.2% sensitivity for HBc, 99.8% for HIV, and 99.1% for HCV, designed for comprehensive bloodborne pathogen screening in a single cartridge.
• Multiplo Rapid TP/HIV/HCV Antibody Test Three-analyte multiplex rapid test for simultaneous detection of HIV-1/2, Treponema pallidum (syphilis), and Hepatitis C virus antibodies. Available for international markets outside North America and EU, designed for combined STI and hepatitis screening programs.
• Miriad Product Line Research Use Only (RUO) rapid test portfolio for multi-marker screening in blood banks, tissue and eye banks, and organ donor programs. Available worldwide without regulatory barriers, featuring single and multiplex configurations including TP, TP/nTP, TP/HIV, HCV/HIV, HBc/HIV/HCV, and TP/HIV/HCV combinations.
• Miriad RVF Toolkit Off-the-shelf research toolkit containing components for creating rapid diagnostic tests using MedMira's RVF Technology. Includes test cartridges, buffer, InstantGold caps, and sample tubes. Enables researchers to develop prototypes for single or multiple biomarker detection, with technical support and a path to commercialization.
• MEDDUO Platform Dual-window antigen and antibody detection platform built on RVF Technology. Supports up to 8 antibody or antigen analytes within one assay with independent detection pathways that prevent cross-interference. Stores at room temperature (2-30°C) with 12-month shelf life, designed for advanced diagnostic applications.
• MiROQ System Next-generation quantitative liquid biopsy system combining RVF Technology with Surface-Enhanced Raman Spectroscopy (SERS). Delivers measurable quantitative results including DNA mutations, gene expression changes, circulating tumor cells, and tumor-derived extracellular vesicles. Features AI-powered data analysis for clinical and research applications.
• VYRA Respiratory Antigen Tests Antigen rapid test platform for respiratory virus detection including SARS-CoV-2, Flu A/B, and RSV. CE marked for European markets with 4-in-1 combination test available, designed for rapid respiratory pathogen screening at point of care.

Quantifiable outcome

• 99.64% HIV-1 sensitivity and 99.71% specificity for Reveal G4 test in whole blood specimens
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

13 partnerships are on record, tiered core, major and minor.

• REACH NexuscoreStrategic or Co-development Partner · 7 July 2025Partnership for clinical trial of Multiplo TP/HIV Self-Test in Canada. REACH Nexus is a research organization focused on improving access to testing for HIV, hepatitis C, and sexually transmitted infections.
• Lovell Government ServicescoreChannel Partner/ Reseller/ Distributor · 17 April 2025Partnership to increase access to Reveal G4 HIV-1/2 rapid test for VA (Veterans Affairs) and Department of Defence healthcare facilities. Lovell serves as a specialized government services distributor for the US military and veteran healthcare market.
• MediGroup Physician ServicescoreChannel Partner/ Reseller/ Distributor · 27 February 2025Partnership for distribution of MedMira rapid diagnostic products to physician practices across the United States. MediGroup provides access to a network of physician practices for point-of-care testing adoption.
• Trimedic Inc.coreChannel Partner/ Reseller/ Distributor · 25 February 2025Exclusive distribution agreement for Canada covering the full MedMira product portfolio including Reveal, Multiplo, and Miriad product lines. Trimedic serves as the exclusive distributor for the Canadian market.
• VWR InternationalcoreChannel Partner/ Reseller/ DistributorGlobal laboratory supply distributor offering Miriad research-use-only products including Miriad TP, TP/nTP, TP/HIV, HCV/HIV, HBc/HIV/HCV, TP/HIV/HCV, and RVF Toolkit. VWR catalog numbers available for ordering.
• MedlinecoreChannel Partner/ Reseller/ DistributorHealthcare supplies distributor offering Miriad research-use-only products. Products include Miriad TP/HIV, HCV/HIV, HBc/HIV/HCV, and RVF Toolkit through Medline's distribution network.
• McKessoncoreChannel Partner/ Reseller/ DistributorHealthcare distribution partner offering Miriad research-use-only products through McKesson's pharmaceutical and medical supply distribution channels.
• Johns Hopkins University Applied Physics LaboratorymajorStrategic or Co-development PartnerCollaboration for validation of multiple STI saliva rapid test development. Johns Hopkins APL provided validation support for the TP/HIV/HCV Saliva Rapid Test using MedMira RVF Technology.
• Washington State University (Professor John Alderete)majorStrategic or Co-development PartnerCollaboration with Professor John Alderete to develop a rapid point-of-care test for Trichomonas vaginalis using MedMira's RVF Technology. The test uses the ACT::SOE3 biomarker and was validated over 12 months.
• Dr. Joaquin Patarroyo (Patsos Biotecnologia, Brazil)minorStrategic or Co-development PartnerResearch collaboration using Miriad RVF Toolkit for development of rapid diagnostic tests. Dr. Patarroyo required an all-in-one solution for research use with technical support to overcome development roadblocks and future commercialization support.
• USAIDmajorGTM or Marketing PartnerNGO and humanitarian partner supporting global health initiatives. USAID works with MedMira to deliver rapid diagnostic solutions in developing countries through humanitarian programs.
• REACH NexusmajorGTM or Marketing PartnerNGO partner focused on improving access to testing for HIV, hepatitis C, and sexually transmitted infections. Collaboration supports global health initiatives in Canada and internationally.
• Public Health WinnipegminorGTM or Marketing PartnerRegional public health organization partnering with MedMira for rapid testing solutions. Public health agencies use MedMira products for STI screening and public health programs.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• OraSure Technologies: OraSure Technologies is a direct peer developing rapid point-of-care infectious disease diagnostics, most notably the OraQuick HIV and OraQuick HCV rapid antibody tests. It competes directly with MedMira in POC infectious disease screening for HIV, hepatitis, and syphilis across clinical, public health, and consumer channels.
• bioLytical Laboratories: bioLytical Laboratories is a Canadian rapid diagnostic test manufacturer specializing in the INSTI HIV-1/2 Antibody Test, with a fingerstick POC format comparable to MedMira's Reveal G4 HIV-1/2 test. Both companies target HIV self-test approvals, public health programs, and global screening markets.
• Trinity Biotech: Trinity Biotech develops and markets diagnostic tests for infectious diseases including HIV, hepatitis, and syphilis, with a portfolio overlapping MedMira's Reveal and Multiplo product lines. The two companies compete in clinical laboratory and point-of-care rapid testing channels globally.
• Chembio Diagnostics: Chembio Diagnostics develops rapid POC diagnostic tests for infectious diseases including HIV, syphilis, and COVID-19 using lateral flow technology, closely overlapping MedMira's rapid infectious disease portfolio. Both target government, NGO, and clinical screening markets.
• SD Biosensor: SD Biosensor is a Korean-based rapid diagnostic test manufacturer with a broad infectious disease portfolio including HIV, hepatitis, syphilis, and respiratory multiplex tests. Comparable to MedMira in delivering multiplexed POC infectious disease assays at global scale.

Broad incumbents

• QuidelOrtho: QuidelOrtho is a broad incumbent in clinical diagnostics with a rapid immunoassay portfolio (e.g., Sofia platform) for infectious disease screening. While not exclusively focused on multiplex RVF, it competes with MedMira across POC testing channels and benefits from larger scale and broader distribution.
• Abbott Rapid Diagnostics (formerly Alere): Abbott's rapid diagnostics franchise, built on the Alere acquisition, dominates HIV (Determine), hepatitis, and syphilis rapid testing globally. It is the dominant incumbent in many of MedMira's target markets and an unavoidable competitor for government and NGO tenders.
• Bio-Rad Laboratories: Bio-Rad Laboratories is a broad life science and diagnostics company offering infectious disease screening assays, including HIV and hepatitis. While larger and more diversified than MedMira, Bio-Rad competes in laboratory and blood-bank screening segments where Miriad products are sold.
• Cepheid (Danaher): Cepheid is a molecular diagnostics leader whose GeneXpert platform provides rapid, decentralized testing for infectious diseases including HIV viral load, HCV, and STI multiplex panels. As MiROQ moves toward quantitative biomarker detection, Cepheid represents a high-scale incumbent competitor in decentralized diagnostics.

Emerging players

• Premier Biotech: Premier Biotech is a smaller US-based rapid diagnostics manufacturer focused on drugs-of-abuse and infectious disease screening tests distributed through similar channels to MedMira. It is comparable as an emerging niche player targeting US distributors, workplace, and clinical screening markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/medmira
• YouTubeyoutube.com/@MedMira-Inc
• LinkedInlinkedin.com/company/medmira-inc-
• Facebookfacebook.com/medmira-297780793667682

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medmira